Kelly CRISPR & Gene Editing Technology ETF Rating → Exposed: 10 CENT Crypto to Explode April 20th? (From True Market Insiders) (Ad) Free XDNA Stock Alerts $7.38 0.00 (0.00%) (As of 04/26/2024 ET) Add Compare Share Share RatingsStock AnalysisChartHeadlinesHoldingsOptions ChainRatingsShort InterestSocial MediaStock AnalysisChartHeadlinesHoldingsOptions ChainRatingsShort InterestSocial Media Kelly CRISPR & Gene Editing Technology ETF Aggregate Rating and Price Target (2024)How MarketBeat Aggregates ETF Rating and Price TargetMarketBeat calculates the aggregate rating and price target for an ETF by considering the weight of each stock in its portfolio. These ratings and price targets are based on the most recent ratings given by Wall Street analysts over the past year. The aggregate rating reviews the ETF's overall performance and is categorized as strong sell, sell, reduce, hold, moderate buy, buy, or strong buy. The aggegreate price target represents the average potential upside for the consensus price target of individual holdings in the ETF.XDNA Aggregate RatingModerate Buy2.60Holdings in XDNA have an aggregate rating of Moderate Buy based on 263 analyst ratings issued in the past year covering 21 companies (94.6% of the portfolio).XDNA Aggregate Price Target$24.52232.23% UpsideHigh Prediction$38.26Average Prediction$24.52Low Prediction$12.70Holdings in XDNA have an aggregate price target of $24.52 and a range of $12.70 to $38.26 covering 21 companies (94.6% of the portfolio).XDNA Consensus Ratings of HoldingsStrong Buy0 Strong Buy rating(s)Buy2 Buy rating(s)Moderate Buy12 Moderate Buy rating(s)Hold7 Hold rating(s)Reduce0 Reduce rating(s)Sell0 Sell rating(s)Strong Sell0 Strong Sell rating(s) Ratings for Stocks Held by Kelly CRISPR & Gene Editing Technology ETF Strong Sell Sell Reduce Hold Moderate Buy Buy Strong Buy Ratings for the Top 21 XDNA Holdings Export to ExcelWeightIn ETFCompanyShare PriceMarketRank™Consensus Rating ScoreConsensus Price TargetPossible UpsideNumber of RatingsIndicator(s)ViewRatings11.05%NTLAIntellia Therapeutics$20.76+3.7%4 of 5 stars2.69$67.00 222.7%13Upcoming EarningsAnalyst ReportNews Coverage10.70%TMOThermo Fisher Scientific$573.60+0.3%5 of 5 stars2.71$606.76 5.8%17Earnings ReportAnalyst ReportAnalyst RevisionNews Coverage9.57%BEAMBeam Therapeutics$21.38-1.0%3 of 5 stars2.38$41.00 91.8%13Analyst Report8.64%CRSPCRISPR Therapeutics$53.91+0.3%3 of 5 stars2.38$76.29 41.5%166.78%CRBUCaribou Biosciences$3.71-1.3%1 of 5 stars2.75$22.50 506.5%4Short Interest ↑5.63%VERVVerve Therapeutics$6.16-1.0%2 of 5 stars2.75$33.00 435.7%85.16%SGMOSangamo Therapeutics$0.52+2.0%1 of 5 stars2.29$4.93 851.1%7Analyst ReportGap Up4.73%PRMEPrime Medicine$4.43+2.8%3 of 5 stars2.70$16.89 281.7%10Analyst Report4.37%ABBVAbbVie$159.62-4.6%5 of 5 stars2.77$177.43 11.2%13Earnings ReportNews CoverageHigh Trading Volume4.13%EDITEditas Medicine$5.32+1.9%4 of 5 stars2.56$15.00 182.0%9Upcoming EarningsShort Interest ↑Analyst RevisionNews Coverage4.10%ALLOAllogene Therapeutics$2.89+1.4%2 of 5 stars2.71$12.94 347.7%7Upcoming Earnings3.32%PSTXPoseida Therapeutics$2.13+3.9%4 of 5 stars3.00$14.67 588.6%32.96%DTILPrecision BioSciences$9.38-3.5%4 of 5 stars3.00$60.00 539.7%2Short Interest ↑2.87%TSVT2seventy bio$4.26-0.9%4 of 5 stars2.38$13.17 209.4%8Upcoming EarningsPositive News2.40%AAgilent Technologies$137.74+1.0%4 of 5 stars2.59$141.29 2.6%17Positive News2.10%BMYBristol-Myers Squibb$44.85+0.3%5 of 5 stars2.11$60.71 35.4%19Earnings ReportAnalyst ReportAnalyst RevisionNews Coverage2.00%ILMNIllumina$122.28+1.0%5 of 5 stars2.32$167.70 37.1%19Upcoming Earnings1.53%VRTXVertex Pharmaceuticals$397.48-0.1%4 of 5 stars2.48$429.45 8.0%231.29%REGNRegeneron Pharmaceuticals$883.20-0.8%4 of 5 stars2.70$977.77 10.7%20Upcoming EarningsAnalyst ReportAnalyst RevisionNews Coverage0.69%QGENQiagen$41.65+1.4%5 of 5 stars2.63$51.69 24.1%8Upcoming EarningsShort Interest ↓News Coverage0.57%BIIBBiogen$208.90+3.2%5 of 5 stars2.67$293.88 40.7%27Earnings ReportAnalyst ReportShort Interest ↓Analyst RevisionNews Coverage This page (NASDAQ:XDNA) was last updated on 4/27/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill PublishingHe Is Giving Away BitcoinCrypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithProtect Your Bank Account Before It’s Too LateWeiss RatingsThey say it’s ‘unstoppable’ – How I made 43,509% Investing DailyBitcoin Rockets To Record High But Buy THIS InsteadParadigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kelly CRISPR & Gene Editing Technology ETF Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
